Assembly Biosciences

Yahoo Finance • last year

Assembly Biosciences Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

SOUTH SAN FRANCISCO, Calif., Nov. 10, 2023 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative antiviral therapeutics targeting serious viral diseases, today announced a grant of i... Full story

Yahoo Finance • last year

Assembly Biosciences Presents New Data Highlighting Viral Hepatitis Portfolio at AASLD The Liver Meeting®

--Poster highlights potential of oral small molecule IFNAR agonist program to engage the IFNα pathway through a liver-focused approach to improve tolerability-- SOUTH SAN FRANCISCO, Calif., Nov. 10, 2023 (GLOBE NEWSWIRE) -- Assembly Bio... Full story

Yahoo Finance • last year

Assembly Biosciences Reports Third Quarter 2023 Financial Results and Recent Updates

Established partnership with Gilead Sciences to advance differentiated treatments for herpesviruses, HBV, HDV and beyondNow anticipate four development candidates from expanded pipeline in clinical development by the end of 2024Named Anuj... Full story

Yahoo Finance • last year

Assembly Biosciences Names Anuj Gaggar, MD, PhD, as Chief Medical Officer

-- Dr. Gaggar is an experienced industry executive with substantial infectious disease expertise and proven record of successfully leading early- and clinical-stage antiviral programs -- SOUTH SAN FRANCISCO, Calif., Nov. 08, 2023 (GLOBE... Full story

Yahoo Finance • last year

Assembly Biosciences to Present New Data at AASLD The Liver Meeting®

-- One poster and one oral presentation selected, with the poster highlighting new preclinical data from the Company’s interferon-α receptor agonist program -- SOUTH SAN FRANCISCO, Oct. 11, 2023 (GLOBE NEWSWIRE) -- Assembly Biosciences,... Full story

Yahoo Finance • last year

Assembly Biosciences Nominates Development Candidate ABI-6250, an Orally Bioavailable HDV Entry Inhibitor

− ABI-6250 demonstrated low nanomolar potency against hepatitis D virus and selective inhibition of NTCP in preclinical studies with once-daily dosing projected – − Progression into clinical studies planned by the end of 2024 – SOUTH SAN... Full story

Yahoo Finance • last year

Assembly Biosciences to Highlight Pipeline Progress in HBV and HDV at the 2023 International HBV Meeting

-- Two oral presentations and one poster will feature new data from the Company’s hepatitis B/hepatitis D entry inhibitor, capsid assembly modulator ABI-4334, and interferon-alpha receptor agonist programs -- SOUTH SAN FRANCISCO, Calif.,... Full story

Yahoo Finance • last year

Assembly Biosciences Presents New Data Highlighting Entry Inhibitor and Core Inhibitor Programs at EASL’s International Liver Congress™ 2023

SOUTH SAN FRANCISCO, Calif., June 21, 2023 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative antiviral therapeutics targeting serious viral diseases, today announced data from it... Full story

Yahoo Finance • 2 years ago

Assembly Biosciences Announces Additional Promising Data from Phase 1a Clinical Trial Evaluating Highly Potent Next-Generation Core Inhibitor Candidate ABI-4334 and Provides Pipeline Update

Phase 1a clinical data for remaining 200 mg multiple dose cohort for ABI-4334 continue to demonstrate encouraging clinical profile with strong projected activity against both viral replication and cccDNA formation Assembly Bio will evaluat... Full story

Yahoo Finance • 2 years ago

Assembly Biosciences Provides Update on its Core Inhibitor Pipeline, Reports Fourth Quarter and Year End 2022 Financial Results and Recent Highlights

Prioritization of core inhibitor candidate ABI-4334 and pausing of core inhibitor candidate ABI-H3733 based on data to date from ongoing clinical Phase 1 studies of both candidates and chronic toxicology observation for ABI-H3733Phase 1a c... Full story

Yahoo Finance • 2 years ago

Assembly Biosciences Nominates First Herpesvirus Development Candidate ABI-5366, a Long-Acting HSV-2 Helicase Inhibitor Targeting High-Recurrence Genital Herpes

−ABI-5366 Demonstrates Favorable Profile for a Long-Acting Therapeutic in Preclinical Studies −IND-Enabling Studies Initiating for 5366, Supporting Anticipated IND/CTA Filing in 1H2024 SOUTH SAN FRANCISCO, Calif., Feb. 15, 2023 (GLOBE... Full story

Yahoo Finance • 2 years ago

Assembly Biosciences Announces Promising Interim Results from Two Clinical Trials Evaluating Highly Potent Next-Generation Core Inhibitor Candidates ABI-H3733 and ABI-4334

In initial ABI-H3733 cohort of 50 mg in 28-day Phase 1b study, six of eight HBV patients on treatment reached lower limit of quantification for HBV DNA by day 21 and patients showed a mean reduction of 3.1 logs in plasma HBV DNA Initial AB... Full story

Yahoo Finance • 2 years ago

Assembly Biosciences Reports Third Quarter 2022 Financial Results and Recent Highlights and Announces Upcoming Conference Participation

Phase 1a Trial of Next-Generation Core Inhibitor, ABI-4334, Now Underway Following Clinical Trial Application (CTA) Clearance SOUTH SAN FRANCISCO, Calif., Nov. 08, 2022 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a cl... Full story

Yahoo Finance • 2 years ago

Assembly Biosciences Presents New Data at AASLD The Liver Meeting® Highlighting Breadth of Virology Portfolio and Potential of Next-Generation Core Inhibitors in HBV

Data demonstrating nanomolar potency of core inhibitor ABI-4334 to disrupt the hepatitis B virus (HBV) life cycle at multiple points supports advancement into clinical studies First data presented on preclinical characterization of potent... Full story

Yahoo Finance • 2 years ago

Assembly Biosciences to Present Data in Four Poster Presentations at Upcoming AASLD The Liver Meeting®

Four poster presentations, including two late breaking, highlight breadth and promise of virology portfolio Data demonstrating preclinical activity of next-generation core inhibitor ABI-4334 against hepatitis B virus supports planned adva... Full story

Yahoo Finance • 2 years ago

Assembly Biosciences to Host Webcast on August 31, 2022, Introducing Two New Research Programs Targeting Recurrent HSV-2 Infection and Transplant-Associated Herpesvirus Diseases

- Renowned virologist, Nobel laureate and Assembly Bio board member, Sir Michael Houghton, PhD, will join company leadership for the discussion - SOUTH SAN FRANCISCO, Calif., Aug. 24, 2022 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc.... Full story

Yahoo Finance • 2 years ago

Assembly Biosciences Reports Second Quarter 2022 Financial Results and Recent Highlights

SOUTH SAN FRANCISCO, Calif., Aug. 09, 2022 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative, investigational therapeutics targeting hepatitis B virus (HBV) and ot... Full story

Yahoo Finance • 2 years ago

Assembly Biosciences Announces Program Reprioritization and Organizational Update

- Discontinues clinical development of vebicorvir, Assembly Bio’s first-generation core inhibitor, based on interim efficacy data from ongoing combination clinical studies - Advancing next-generation, significantly more potent core inhibi... Full story

Yahoo Finance • 2 years ago

Assembly Biosciences Presents New Data Highlighting Clinical Progress of Core Inhibitor Programs at EASL’s International Liver Congress™ 2022

SOUTH SAN FRANCISCO, Calif., June 22, 2022 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative, investigational therapeutics targeting hepatitis B virus (HBV) and ot... Full story

Yahoo Finance • 2 years ago

Assembly Biosciences to Introduce New Small Molecule Liver-Focused Interferon-α Receptor Agonist Research Program in Webcast on July 26, 2022

Assembly Bio leadership team will be joined by Professor Edward J. Gane, MBCHB, MD, FRACP, MNZM​, an internationally-recognized hepatologist, and authority and investigator in hepatitis clinical trials SOUTH SAN FRANCISCO, Calif., June 2... Full story